Bifogade filer
ASCELIA PHARMA ANNOUNCES ACCEPTANCE OF ORVIGLANCE DATA FOR ORAL PRESENTATION AT THE ANNUAL RADIOLOGY CONGRESS ESGAR 2026
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with an evaluation of the detection of focal liver lesions with Orviglance contrast agent from two phase 2 studies has been accepted for oral presentation at the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Annual Meeting, taking place 9-12 June in Montpellier, France.
The abstract titled “Diagnostic Value of Manganese-Based Contrast Agent (ACE-MBCA) vs Unenhanced MRI in Liver Lesion Detection: Re-analysis of STAR Study Images from Two Phase II Clinical Trials”, demonstrated that Orviglance significantly improves the detection of focal liver lesions compared to unenhanced MRI. The findings underline the potential of Orviglance as a new contrast agent for liver MRI.
“We are excited that an abstract with Orviglance data has been selected for oral presentation at ESGAR, one of the leading global forums for innovation in gastrointestinal and abdominal imaging. This recognition highlights the growing scientific interest in manganese-based contrast agents”, says Andreas Norlin, CSO of Ascelia Pharma.
Presenting author: Dr. D. Geisel (Charité - Universitätsmedizin Berlin, Germany)
Timing of presentation: 9 June 2026, 10:00 - 10:30 CET
Ascelia Pharma has submitted the New Drug Application (NDA) for Orviglance to the US Food and Drug Administration (FDA) with expected approval date of 3 July 2026.